Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.57 |
| ▸ | MEN1 | O00255 | 5/20 | 0.57 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3054171 | 1.00 | KMT2A (0.57) | KMT2AMEN1ADRA2BADRA2CSLC6A2 | |
| SCHEMBL7144646 | 1.00 | KMT2A (0.57) | KMT2AMEN1ADRA2BADRA2CSLC6A2 | |
| Hydrochloric Acid SCHEMBL29247750 | 0.98 | KMT2A (0.56) | KMT2AMEN1ADRA2BADRA2CSLC6A2 | |
| SCHEMBL10140576 | 0.87 | KMT2A (0.57) | KMT2AMEN1ADRA2BADRA2CSLC6A2 | |
| SCHEMBL890170 | 0.87 | KMT2A (0.56) | KMT2AMEN1ADRA2BADRA2CSLC6A2 | |
| SCHEMBL9267301 | 0.87 | KMT2A (0.56) | KMT2AMEN1ADRA2BADRA2CSLC6A2 | |
| SCHEMBL888819 | 0.85 | KMT2A (0.55) | KMT2AMEN1ADRA2BADRA2CSLC6A2 | |
| SCHEMBL17372647 | 0.85 | KMT2A (0.55) | KMT2AMEN1ADRA2BADRA2CSLC6A2 | |
| SCHEMBL19182844 | 0.85 | KMT2A (0.55) | KMT2AMEN1ADRA2BADRA2CSLC6A2 | |
| SCHEMBL13484482 | 0.85 | KMT2A (0.55) | KMT2AMEN1ADRA2BADRA2CSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0319814-B1 | METHOD OF PREPARING ASYMMETRICAL DIHYDROPYRIDINES | BAYER AG (DE) | 1992-09-16 | — | — | EP | claimed |
| EP-0319814-A2 | Method of preparing asymmetrical dihydropyridines | BAYER AG (DE) | 1989-06-14 | — | — | EP | claimed |
| EP-3794944-B1 | SAFENER | NIPPON SODA CO (JP) | 2023-10-18 | — | — | EP | disclosed |
| US-11753398-B2 | Therapeutic compounds | C4X DISCOVERY LIMITED (GB) | 2023-09-12 | — | — | US | disclosed |
| WO-2023286855-A1 | FORMAMIDE DERIVATIVE AND AGRICULTURAL OR HORTICULTURAL PLANT DISEASE CONTROL AGENT | クミアイ化学工業株式会社 | 2023-01-19 | — | — | WO | disclosed |
| WO-2022239840-A1 | STORAGE OF MICROORGANISM HAVING PLANT PROTECTING ABILITY | 日本曹達株式会社 | 2022-11-17 | — | — | WO | disclosed |
| CN-112272518-B | Chemical injury lightening agent | 日本曹达株式会社 | 2022-06-07 | — | — | CN | disclosed |
| US-20210395227-A1 | THERAPEUTIC COMPOUNDS | INDIVIOR UK LIMITED (GB) | 2021-12-23 | — | — | US | disclosed |
| US-11130746-B2 | Therapeutic compounds | C4X DISCOVERY LIMITED (GB) | 2021-09-28 | — | — | US | disclosed |
| US-20210227825-A1 | SAFENER | NIPPON SODA CO., LTD. (JP) | 2021-07-29 | — | — | US | disclosed |
| CN-112654621-A | Substituted naphthyridinone compounds useful as T cell activators | 百时美施贵宝公司 | 2021-04-13 | — | — | CN | disclosed |
| US-6451854-B1 | α-amino acid phenyl ester derivatives | AKZO NOBEL N.V. (NL) | 2002-09-17 | — | — | US | disclosed |
| EP-1098871-A1 | $g(a)-AMINO ACID PHENYL ESTER DERIVATIVES | Akzo Nobel N.V. (NL) | 2001-05-16 | — | — | EP | disclosed |
| CN-1053657-C | Didepsipeptide-based endoparasiticidal compositions, novel depsipeptides and methods for their preparation | BAYER AG (DE) | 2000-06-21 | — | — | CN | disclosed |
| WO-2000005196-A1 | α-AMINO ACID PHENYL ESTER DERIVATIVES | AKZO NOBEL N.V. (NL) | 2000-02-03 | — | — | WO | disclosed |
| EP-0349330-B1 | Photographic material and process (B) | EASTMAN KODAK CO (US) | 1995-03-29 | — | — | EP | disclosed |
| EP-0319814-B1 | METHOD OF PREPARING ASYMMETRICAL DIHYDROPYRIDINES | BAYER AG (DE) | 1992-09-16 | — | — | EP | disclosed |
| EP-0349330-A2 | Photographic material and process (B) | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1990-01-03 | — | — | EP | disclosed |
| US-4857440-A | RELEASING DYE UPON OXIDATIVE DEVELOPMENT OF SILVER HALIDE EMULSION | EASTMAN KODAK COMPANY (US) | 1989-08-15 | — | — | US | disclosed |
| US-4145432-A | 6-ACYLORYALKYL-1,4-DIHYDROPYRIDINE DERIVATIVES AND A METHOD OF EFFECTING VASODILATION THEREWITH | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1979-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753398-B2 | Therapeutic compounds | HCRTR2, HCRTR1, NPY1R | KMT2A 2027/4885MEN1 713/4885ADRA2B 200/4885 |
| US-11130746-B2 | Therapeutic compounds | HCRTR2, HCRTR1, NPY1R | KMT2A 2027/4885MEN1 713/4885ADRA2B 200/4885 |
| US-20210227825-A1 | SAFENER | CYP2W1, CYP4Z1, WEE1 | KMT2A 452/4885MEN1 2522/4885ADRA2B 2104/4885 |
| US-20210395227-A1 | THERAPEUTIC COMPOUNDS | HCRTR2, HCRTR1, NPY1R | KMT2A 2027/4885MEN1 713/4885ADRA2B 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.